Recent Updates
Recently added Catalysts

Fixed-Dose Combination

Phase 1

Healthy Volunteer Study | Small molecule | Other |NewAmsterdam Pharma Company N.V.|Last Updated: Jun 4, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment28
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06050291Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and EzetimibePHASE1 COMPLETED 28 — — Jan 1, 2024Apr 1, 2024Jun 4, 2024 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Fixed-Dose Combination (FDC) TabletDRUGObicetrapib/Ezetimibe FDC tablet
Unlock Study Design Details